Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2399-3669
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model ; volume:2 ; number:1 ; day:22 ; month:3 ; year:2019 ; pages:1-14 ; date:12.2019
Communications chemistry ; 2, Heft 1 (22.3.2019), 1-14, 12.2019
- Urheber
-
Dighe, Satish N.
De la Mora, Eugenio
Chan, Stephen
Kantham, Srinivas
McColl, Gawain
Miles, Jared A.
Veliyath, Suresh Kumar
Sreenivas, B. Yogi
Nassar, Zeyad D.
Silman, Israel
Sussman, Joel L.
Weik, Martin
McGeary, Ross P.
Parat, Marie-Odile
Brazzolotto, Xavier
Ross, Benjamin P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s42004-019-0133-4
- URN
-
urn:nbn:de:101:1-2019041101081194325889
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dighe, Satish N.
- De la Mora, Eugenio
- Chan, Stephen
- Kantham, Srinivas
- McColl, Gawain
- Miles, Jared A.
- Veliyath, Suresh Kumar
- Sreenivas, B. Yogi
- Nassar, Zeyad D.
- Silman, Israel
- Sussman, Joel L.
- Weik, Martin
- McGeary, Ross P.
- Parat, Marie-Odile
- Brazzolotto, Xavier
- Ross, Benjamin P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review